New York, April 16, 2024 - PRISM MarketView - Precision diagnostics company, Oncocyte Corporation (Nasdaq: OCX), has entered a strategic partnership with Bio-Rad Laboratories (NYSE: BIO), for the commercialization of its GraftAssure™ assay, a blood-based solid organ transplantation monitoring test powered by Droplet Digital™ PCR (ddPCR™). The new Research Use Only product is designed to detect signs of graft damage and is expected to launch to select academic transplant centers in the US and EU in the second quarter of 2024, and more broadly in the second half of the year.
Globally, over 157,000 transplants are performed each year with a 9.1% annual growth rate. Oncocyte is pursuing an estimated market of more than three million testing opportunities globally, valued at over $1 billion.
“As we move towards launch, having the support of the Bio-Rad team in the US and Germany gives us the scale we need to meet the market opportunity. The QX600 ddPCR platform, along with their expertise in serving the life science market, makes Bio-Rad a natural partner for our transplant technology.”
Josh Riggs, Oncocyte’s CEO
Bio-Rad Laboratories is a global leader in life science research and clinical diagnostics products.
Deal Highlights
- Under the terms of the agreement, Bio-Rad and Oncocyte will co-market the GraftAssure™ assay in the US and Germany, where Oncocyte will act as commercial lead.
- Bio-Rad has been granted exclusive global distribution and commercial rights outside the US and Germany.
- Both companies have committed to the development of a regulated product designed to facilitate widespread distribution and clinical adoption in the United States and beyond.
- Bio-Rad has been granted an option for in vitro diagnostic (IVD) commercial rights when FDA clearance is achieved, subject to meeting specific objectives. Exercising the option would come with a second equity investment into Oncocyte.
About Oncocyte
Oncocyte is a precision diagnostics company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood- based solid organ transplantation monitoring test, which recently received CMS reimbursement for kidney transplantation. GraftAssure™ is a decentralized research use only blood-based solid organ transplantation monitoring test, DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and the pipeline test DetermaCNI™ is blood-based monitoring tool for assessing therapeutic efficacy.
VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.
Oncocyte Corporation (Nasdaq: OCX) is featured on PRISM Emerging MedDevices Index
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities
PRISM MarketView - Social Media (X)